What is the share price of Anthem Biosciences Ltd (ANTHEM) today?
The share price of ANTHEM as on 7th November 2025 is ₹696.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Anthem Biosciences Ltd (ANTHEM) share?
The past returns of Anthem Biosciences Ltd (ANTHEM) share are- Past 1 week: -3.06%
- Past 1 month: -9.06%
- Past 3 months: -7.08%
- Past 6 months: -4.63%
- Past 1 year: -4.63%
- Past 3 years: N/A%
- Past 5 years: -4.63%
What are the peers or stocks similar to Anthem Biosciences Ltd (ANTHEM)?
The peers or stocks similar to Anthem Biosciences Ltd (ANTHEM) include:What is the market cap of Anthem Biosciences Ltd (ANTHEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Anthem Biosciences Ltd (ANTHEM) is ₹39118.95 Cr as of 7th November 2025.What is the 52 week high and low of Anthem Biosciences Ltd (ANTHEM) share?
The 52-week high of Anthem Biosciences Ltd (ANTHEM) is ₹873.50 and the 52-week low is ₹686.What is the PE and PB ratio of Anthem Biosciences Ltd (ANTHEM) stock?
The P/E (price-to-earnings) ratio of Anthem Biosciences Ltd (ANTHEM) is 86.69. The P/B (price-to-book) ratio is 16.23.Which sector does Anthem Biosciences Ltd (ANTHEM) belong to?
Anthem Biosciences Ltd (ANTHEM) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Anthem Biosciences Ltd (ANTHEM) shares?
You can directly buy Anthem Biosciences Ltd (ANTHEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Anthem Biosciences Ltd
ANTHEM Share Price
696.550.01% (-0.05)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ANTHEM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ANTHEM Performance & Key Metrics
ANTHEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 16.23 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.70 | 5.79 | 0.59% |
0%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
ANTHEM Company Profile
Anthem Biosciences Limited is an Indian CRDMO offering integrated drug discovery, development, and manufacturing services for biotech and pharma clients including proteins, antibodies, peptides, and highly potent compounds.
BIOCON
PE Ratio
50.12
50.12
1Y Return
15.98%
15.98%
Buy Reco %
68.75
68.75
ONESOURCE
PE Ratio
-1,133.52
-1,133.52
1Y Return
3.95%
3.95%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
108.15
108.15
1Y Return
14.49%
14.49%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
91.04
91.04
1Y Return
70.99%
70.99%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-303.04
-303.04
1Y Return
10.99%
10.99%
Buy Reco %
0.00
0.00
ANTHEM Sentiment Analysis
ANTHEM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ANTHEM Stock Summary · August 2025
In Q1 FY26, the company demonstrated robust year-on-year growth, primarily fueled by its CRDM revenue stream and heightened demand for commercial products, resulting in consolidated revenues of INR 540 crores. However, management remains cautious about future revenue consistency due to variable customer behaviors and operational challenges, including lengthy approval processes and rising costs from facility expansions. While optimistic about maintaining a long-term growth outlook of approximately 20% CAGR, the company is also focused on enhancing R&D capabilities and expanding its custom synthesis and fermentation capacities to meet anticipated demand. Strategic engagement with large pharmaceutical clients, particularly in the GLP-1 market, positions the company favorably, despite uncertainties surrounding new product commercialization and market dynamics. Overall, a proactive approach to capacity expansion and customer relationships underscores the company's commitment to navigating market complexities while pursuing sustainable growth.
ANTHEM Stock Growth Drivers
ANTHEM Stock Growth Drivers
7Strong Financial Performance
The company reported a consolidated revenue of INR 540 crores for Q1 FY26, with significant
Capacity Expansion Initiatives
The company is actively expanding its capacity, with plans to increase custom synthesis capacity by
ANTHEM Stock Challenges
ANTHEM Stock Challenges
4Gross Margin Decline
The company has experienced a significant quarter-on-quarter decline in gross margins, attributed to a share-based
Lumpiness of Business Performance
Management has emphasized the inherent variability in their business, indicating that the exceptional revenue increase
ANTHEM Forecast
ANTHEM Forecasts
Price
Revenue
Earnings
ANTHEM Share Price Forecast
ANTHEM Share Price Forecast
2025
Current
₹696.55
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹696.55
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ANTHEM Company Revenue Forecast
ANTHEM Company Revenue Forecast
2025
Current
₹1.93
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.93
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ANTHEM Stock EPS (Earnings Per Share) Forecast
ANTHEM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹8.07
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹8.07
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ANTHEM
ANTHEM
Income
Balance Sheet
Cash Flow
Annual Normal View
ANTHEM Income Statement
ANTHEM Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 653.48 | 1,140.45 | 1,280.24 | 1,195.79 | 1,483.07 | 1,930.28 | — | |||||||
Raw Materials | 284.29 | 407.88 | 410.30 | 348.29 | 640.79 | 830.62 | — | |||||||
| Power & Fuel Cost | 30.42 | 34.23 | 36.33 | 39.01 | 32.13 | 48.18 | ||||||||
| Employee Cost | 120.15 | 142.19 | 137.51 | 153.24 | 182.93 | 260.09 | ||||||||
| Selling & Administrative Expenses | 31.83 | 33.68 | 48.30 | 60.79 | 55.19 | 64.52 | ||||||||
| Operating & Other expenses | -15.89 | 77.54 | 33.82 | 24.75 | 3.23 | -29.89 | ||||||||
EBITDA | 202.68 | 444.93 | 613.98 | 569.71 | 568.80 | 756.76 | — | |||||||
| Depreciation/Amortization | 61.58 | 62.40 | 57.76 | 63.70 | 81.82 | 89.37 | — | |||||||
| PBIT | 141.10 | 382.53 | 556.22 | 506.01 | 486.98 | 667.39 | — | |||||||
| Interest & Other Items | 20.43 | 16.97 | 10.09 | 8.72 | 9.66 | 10.53 | — | |||||||
| PBT | 120.67 | 365.56 | 546.13 | 497.29 | 477.32 | 656.86 | — | |||||||
| Taxes & Other Items | 27.96 | 94.27 | 140.60 | 112.11 | 110.01 | 205.61 | — | |||||||
| Net Income | 92.71 | 271.29 | 405.53 | 385.18 | 367.31 | 451.25 | — | |||||||
| EPS | 1.70 | 4.95 | 7.23 | 6.75 | 6.50 | 8.07 | — | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
ANTHEM Company Updates
FY 2026FY 2026
Investor Presentation
Aug 13PDF
ANTHEM Stock Peers
ANTHEM Past Performance & Peer Comparison
ANTHEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Anthem Biosciences Ltd | 86.69 | 16.23 | — |
| Biocon Ltd | 50.12 | 1.83 | 0.12% |
| Onesource Specialty Pharma Ltd | -1,133.52 | 3.46 | — |
| Sai Life Sciences Ltd | 108.15 | 8.64 | — |
ANTHEM Stock Price Comparison
Compare ANTHEM with any stock or ETFCompare ANTHEM with any stock or ETF
ANTHEM
ANTHEM Holdings
ANTHEM Shareholdings
ANTHEM Promoter Holdings Trend
ANTHEM Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ANTHEM Institutional Holdings Trend
ANTHEM Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 3.59%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ANTHEM Shareholding Pattern
ANTHEM Shareholding Pattern
ANTHEM Shareholding History
ANTHEM Shareholding History
Foreign Institutions
Mutual Funds Invested in ANTHEM
Mutual Funds Invested in ANTHEM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Anthem Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6685% | Percentage of the fund’s portfolio invested in the stock 0.86% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 74/118 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4332% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.97% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 67/87 (+12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3833% | Percentage of the fund’s portfolio invested in the stock 1.21% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/98 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ANTHEM stock
smallcases containing ANTHEM stock
Looks like this stock is not in any smallcase yet.
ANTHEM Events
ANTHEM Events
ANTHEM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ANTHEM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ANTHEM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ANTHEM has not given any dividends in last 5 years
ANTHEM Dividends
ANTHEM Dividends
Hmm, looks like data is unavailable here. Please come back after some timeANTHEM Stock News & Opinions
ANTHEM Stock News & Opinions
Articles & Videos
Corporate
Anthem Biosciences to announce Quarterly Result
Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Anthem Biosciences consolidated net profit rises 64.83% in the June 2025 quarter
Net profit of Anthem Biosciences rose 64.83% to Rs 135.79 crore in the quarter ended June 2025 as against Rs 82.38 crore during the previous quarter ended June 2024. Sales rose 59.55% to Rs 540.21 crore in the quarter ended June 2025 as against Rs 338.59 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales540.21338.59 60 OPM %35.4535.71 - PBDT212.69136.65 56 PBT186.25117.98 58 NP135.7982.38 65 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Anthem Biosciences to declare Quarterly Results
Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Anthem Biosciences jumps on debut
The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price. So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far. The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 24.19%, vs industry avg of 21.23%
Over the last 5 years, market share increased from 7.16% to 8.08%
Over the last 5 years, net income has grown at a yearly rate of 37.23%, vs industry avg of 23.38%